Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
ALDERLEY PARK - TheraCryf plc (AIM:TCF), a drug development company specializing in neuropsychiatry and oncology, announced it will host an investor webinar Wednesday to discuss its Ox-1 addiction program. The session, scheduled for 11:30am BST, will be led by the company’s Chief Business Officer, Dr. Helen Kuhlman, and neuroscientist Dr. Fraser Murray.
The webinar aims to provide a detailed overview of the Ox-1 program, which is part of TheraCryf’s broader focus on addressing brain disorders. The company’s pipeline includes clinical and preclinical projects targeting conditions such as addiction, anxiety, fatigue, narcolepsy, and glioblastoma—an orphan indication.
Investors interested in attending the webinar can access the session through the Investor Meet Company platform. Existing followers of TheraCryf on the platform have been automatically invited, while new participants can register for free.
TheraCryf’s strategy involves advancing its programs to clinical or preclinical proof of concept and then partnering with mid-size to large pharmaceutical companies for further trials and commercialization. The company has established industry partnerships, including with Stalicla SA for neurodevelopmental disorders, and has sourced expertise from companies like Shire, now part of Takeda.
Collaborations with major academic and medical institutions, such as the University of Manchester, La Sapienza University of Rome, Erasmus Medical (TASE:BLWV) Centre in Rotterdam, King’s College London, and the University of Michigan, have been integral to TheraCryf’s development efforts.
Headquartered at Alderley Park in Cheshire, TheraCryf is listed on the AIM market of the London Stock Exchange (LON:LSEG) under the ticker TCF.
This article is based on a press release statement from TheraCryf plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.